Implanet Joins the EnterNext© PEA-PME 150 Index

BORDEAUX, France & BOSTON--()--Regulatory News :

“We are delighted to have been chosen to incorporate this new index, which will enable us to benefit from greater visibility within the financial community. Being selected will also help increase our share’s appeal and our capital’s accessibility among investors.”

IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, announces that it has been chosen to be included in the EnterNext© PEA-PME 150 index, which is being launched today.

This new index comprises 150 French companies that are accompanied by EnterNext, listed on the Euronext and Alternext markets in Paris and among the 80% most traded PEA-PME eligible shares. The rankings within the index are based on free float market capitalization.

The creation of the EnterNext PEA-PME 150 index is part of EnterNext’s active policy of striving to increase the visibility of small and midcaps among investors. It aims to meet the demands of French industry for the creation a benchmark index for mid-range PEA-PME eligible shares. This index provides investors with a benchmark regarding the stock market performances of listed French SMEs with the greatest free float market capitalization.

Ludovic Lastennet, CEO of Implanet, says: “We are delighted to have been chosen to incorporate this new index, which will enable us to benefit from greater visibility within the financial community. Being selected will also help increase our share’s appeal and our capital’s accessibility among investors.

About IMPLANET

Founded in 2007 and based near Bordeaux, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2013 sales of €6.7 million. For further information, please visit www.implanet.com.

IMPLANET is listed on Compartment C of Euronext™ Paris.
Ticker: IMPL - ISIN code: FR0010458729

Contacts

IMPLANET
Ludovic Lastennet, Tel.: +33 (0)5 57 99 55 55
CEO
investors@implanet.com
or
NewCap
Investor Relations
Florent Alba, Tel.: +33 (0)1 44 71 94 94
implanet@newcap.fr
or
NewCap
Press Relations
Nicolas Merigeau, Tel.: +33 (0)1 44 71 94 98
implanet@newcap.fr

Recent Stories

RSS feed for IMPLANET

Release Summary

Implanet joins the EnterNext© PEA-PME 150 index

IMPLANET